RxDoctor Payments Data

James Towery, MD

Interventional Cardiology · Birmingham, ALNPI 1497966287

Payments from drug & device makers

$6,388in general payments, 2019–2025

Across 166 payments — averaging $38.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Novartis$902
  • Pfizer$252
  • Johnson & Johnson$237
  • Abbott$217
  • Boehringer Ingelheim$124
  • plus $636 from 15 others

What the payments were for

  • Travel & lodging$3,46954%
  • Food & beverage$2,91946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,388 in reported general payments places this provider in the 35th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$385,495
Medicare patients
764
Services billed
3,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban707$522,606
XareltoRivaroxaban60$41,312
Repatha SureclickEvolocumab52$34,206
EntrestoSacubitril/Valsartan46$33,598
JardianceEmpagliflozin38$28,086
MultaqDronedarone Hcl22$17,102
FarxigaDapagliflozin Propanediol19$12,612
Ranolazine ErRanolazine93$7,203
Metoprolol Succinate475$6,927
Flecainide Acetate111$5,851
Atorvastatin Calcium302$4,695
NexlizetBempedoic Acid/Ezetimibe12$4,579
Dabigatran EtexilateDabigatran Etexilate Mesylate17$2,432
Losartan Potassium121$2,413
Chlorthalidone91$2,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$252$522,606707 claims
Johnson & JohnsonXarelto$237$41,31260 claims
NovartisEntresto$902$33,59846 claims
Boehringer IngelheimJardiance$124$28,08638 claims
Sanofi-aventis U.S. LLCMultaq$110$17,10222 claims
AstraZenecaFarxiga$39$12,61219 claims
Esperion Therapeutics, Inc.Nexlizet$39$4,57912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →